Can AstraZeneca Navigate Its Pipeline Waters?

Cost-cutting should help AstraZeneca navigate through its major patent cliff and thin pipeline

Damien Conover, CFA 6 January, 2012 | 4:17PM
Facebook Twitter LinkedIn

AstraZeneca's (AZN) leading presence in the pharma and biotech industry is built on patent-protected drugs and a developing pipeline that all add up to a wide moat. The firm's dynamic operations and an aggressive acquisition strategy create growth opportunities to offset patent losses, including the near-term expirations of neurology drug Seroquel and oncology drug Arimidex.

Although AstraZeneca's pipeline ranks toward the bottom of its peer group, we think the company is developing several key products that hold blockbuster potential. In particular, dapagliflozin could enjoy a first-mover advantage as a new type of diabetes therapy.

Although the company creates growth opportunities through acquisitions, its checkered track record leaves us less confident of management's adherence to price discipline.

Additionally, besides both internal and external product development, Astra is significantly cutting costs to mitigate lost profits from products losing patent protection. The cost savings should help the company navigate the patent losses on several high-margin drugs.

Morningstar Analyst Notes and Research are available to Premium subscribers. Sign up for a free two-week trial for instant access to the full research report on AstraZeneca, including our fair value estimate and economic moat.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
AstraZeneca PLC10,946.00 GBX0.29Rating

About Author

Damien Conover, CFA  is an equity analyst and associate director at Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures